Skin Cancer Diagnostics Market Report 2026

The skin cancer diagnostics market size has grown strongly in recent years. It will grow from $3.38 billion in 2025 to $3.66 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising incidence of skin cancers, limited early detection options, growth in dermatology clinics, reliance on biopsies, increased public awareness campaigns.

The skin cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to adoption of AI and imaging diagnostics, growth in non-invasive molecular techniques, expansion of teledermatology, increasing early detection initiatives, integration with personalized treatment plans. Major trends in the forecast period include rise in non-invasive diagnostic techniques, integration with AI-based skin imaging, adoption of molecular diagnostics, growth in early detection programs, expansion in teledermatology platforms.

The rising incidence of melanoma is expected to drive the growth of the skin cancer diagnostics market in the coming years. Melanoma is a form of skin cancer that develops in the cells responsible for producing melanin, the pigment that gives color to the skin, hair, and eyes. Skin cancer diagnostics play a vital role in detecting and characterizing skin lesions, supporting early diagnosis, accurate evaluation, and effective treatment planning. For example, in 2023, the American Cancer Society Inc., a US-based nationwide voluntary health organization focused on cancer prevention, reported that the number of men diagnosed with melanoma in the United States increased from 57,180 in 2022 to 58,120 in 2023. Additionally, according to the American Society of Clinical Oncology in March 2023, melanoma represents about 1% of all skin cancers diagnosed in the US but accounts for the majority of skin cancer-related deaths, with an estimated 7,990 fatalities in 2023 (5,420 men and 2,570 women). Therefore, the rising number of melanoma cases is fueling the growth of the skin cancer diagnostics market.

Companies in the skin cancer diagnostics market are increasingly focusing on advanced solutions, such as AI-powered pop-up clinics, to gain a competitive edge. An AI-powered pop-up clinic is a temporary healthcare setup that leverages artificial intelligence to provide rapid and technologically advanced medical services at a specific location or for a targeted purpose. For instance, in January 2023, Skin Check Champions, an Australia-based health charity promoting skin health awareness, partnered with The University of South Australia and The Hospital Research Foundation, to launch an AI-powered pop-up clinic for skin cancer diagnosis. Managed by nurses, the clinic captures high-resolution images of patient lesions, which are then analyzed by AI algorithms for preliminary malignancy assessment. The results are subsequently verified by local general practitioners (GPs).

In March 2025, Gestalt Diagnostics, a US-based provider of digital pathology solutions, collaborated with Primaa to enhance skin cancer detection using AI-driven diagnostic tools. The partnership aims to combine Primaa’s deep-learning dermatopathology algorithms with Gestalt’s digital pathology platform to improve diagnostic accuracy, streamline clinical workflows, and support early detection of melanoma and other skin cancers. This collaboration enhances patient outcomes and facilitates scalable adoption of AI in clinical dermatopathology. Primaa is a France-based AI-focused dermatopathology company specializing in precision skin cancer diagnostics.

Major companies operating in the skin cancer diagnostics market are Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Novartis AG, Bristol-Myers Squibb Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Genentech, Castle Biosciences, DermTech Inc., SkylineDx BV, DermLite LLC, Biolitec Ag, Alma Lasers, AMLo Biosciences Limited, National Cancer Institute, Almirall.

North America was the largest region in the skin cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skin cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the skin cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the skin cancer diagnostics market by raising prices for imported imaging systems, biopsy tools, molecular diagnostic kits, and laboratory equipment. Hospitals, clinics, and diagnostic laboratories in Asia-Pacific and Europe are particularly affected due to reliance on international diagnostic technology providers. These cost pressures can slow the adoption of advanced melanoma and carcinoma detection methods. On the positive side, tariffs are encouraging regional production of diagnostic reagents and devices, strengthening local diagnostic infrastructure in the skin cancer diagnostics market.

The skin cancer diagnostics market research report is one of a series of new reports that provides skin cancer diagnostics market statistics, including skin cancer diagnostics industry global market size, regional shares, competitors with a skin cancer diagnostics market share, detailed skin cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer diagnostics industry. This skin cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Skin cancer diagnostics refers to the methods and procedures used by healthcare professionals to detect and confirm the presence of skin cancer in patients. These diagnostics generally involve a combination of clinical examinations, imaging techniques, and laboratory tests to evaluate suspicious skin lesions and determine the extent and characteristics of the cancer.

The main types of skin cancer diagnostics include basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and others. Basal cell carcinoma is the most common type of skin cancer, originating from the basal cells in the lower layer of the skin’s epidermis. The approaches include both diagnosis and therapeutics and are widely utilized in hospitals, clinics, laboratories, and other healthcare settings.

The skin cancer diagnostics market consists of revenues earned by entities by providing skin cancer diagnostics services such as diagnostic tests, visual inspection, dermoscopy, biopsy, imaging techniques (ultrasound, CT scan, MRI), laboratory tests (immunohistochemistry, molecular testing, genetic analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. The skin cancer diagnostics market also includes sales of dermatoscopes, biopsy tools, imaging equipment (ultrasound, CT scanners, MRI machines), molecular testing kits, immunohistochemistry (IHC) kits, and laboratory analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.